Research programme: skin disorder therapies - York Pharma

Drug Profile

Research programme: skin disorder therapies - York Pharma

Alternative Names: Skin protease inhibitors - York Pharma; VAMP inhibitors - York Pharma; Vitamin A metabolic pathway inhibitors - York Pharma; YP 003 programme - York Pharma; YP 004

Latest Information Update: 04 Apr 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator York Pharma
  • Class
  • Mechanism of Action Peptide hydrolase inhibitors; Retinoic acid metabolism modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atopic dermatitis; Malignant melanoma; Psoriasis

Most Recent Events

  • 24 Feb 2006 Preclinical trials in Malignant melanoma in United Kingdom (unspecified route)
  • 13 Sep 2005 Preclinical trials in Atopic dermatitis in United Kingdom (Topical)
  • 13 Sep 2005 Preclinical trials in Psoriasis in United Kingdom (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top